The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site

Molecular Therapy

Volumn 22, Issue 11, 2014, Pages 1936-1948

  Alonso Camino, Vanesa ^a   Rajani, Karishma ^a   Kottke, Timothy ^a   Rommelfanger Konkol, Diana ^a   Zaidi, Shane ^a   Thompson, Jill ^a   Pulido, Jose ^a,b   Ilett, Elizabeth ^c   Donnelly, Oliver ^c   Selby, Peter ^c   Pandha, Hardev ^d   Melcher, Alan ^c   Harrington, Kevin ^a   Diaz, Rosa Maria ^a   Vile, Richard ^a,c,e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CELL ANTIGEN; COMPLEMENTARY DNA; CYTC C ANTIGEN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MYC PROTEIN; N RAS ANTIGEN; ONCOLYTIC VIRUS; TRANSCRIPTION FACTOR SOX10; TUMOR ANTIGEN; TYRP 1 ANTIGEN; UNCLASSIFIED DRUG; VIRUS T ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; ASMEL CELL LINE; BRAIN CANCER; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CD11B+ CELL; CELL LINE; CONTROLLED STUDY; DNA LIBRARY; DRUG EFFICACY; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFER; MALE; MELANOMA; MELANOMA B16; MELANOMA CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; SUBCUTANEOUS TISSUE TUMOR; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; VESICULOVIRUS; ADMINISTRATION AND DOSAGE; ANIMAL; ANTIBODY SPECIFICITY; BRAIN NEOPLASMS; C57BL MOUSE; GENE LIBRARY; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA, EXPERIMENTAL; METABOLISM; PROCEDURES; T LYMPHOCYTE; TUMOR CELL LINE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIGENS, VIRAL, TUMOR; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE LIBRARY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; VESICULOVIRUS;

EID: 84964312939     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.134     Document Type: Article

References (40)

1. Barber, GN (2004). Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 17: 516-527.
2. Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J et al. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848.
3. Galivo, F, Diaz, RM, Thanarajasingam, U, Jevremovic, D, Wongthida, P, Thompson, J et al. (2010). Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther 21: 439-450.
4. Galivo, F, Diaz, RM, Wongthida, P, Thompson, J, Kottke, T, Barber, G et al. (2010). Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 17: 158-170.
5. Wongthida, P, Diaz, RM, Galivo, F, Kottke, T, Thompson, J, Melcher, A et al. (2011). VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther 19: 150-158.
6. Wongthida, P, Diaz, RM, Galivo, F, Kottke, T, Thompson, J, Pulido, J et al. (2010). Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 70: 4539-4549.
7. Qiao, J, Kottke, T, Willmon, C, Galivo, F, Wongthida, P, Diaz, RM et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
8. Wongthida, P, Diaz, RM, Pulido, C, Rommelfanger, D, Galivo, F, Kaluza, K et al. (2011). Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther 22: 1343-1353.
9. Bridle, BW, Stephenson, KB, Boudreau, JE, Koshy, S, Kazdhan, N, Pullenayegum, E et al. (2010). Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18: 1430-1439.
10. Castelo-Branco, P, Passer, BJ, Buhrman, JS, Antoszczyk, S, Marinelli, M, Zaupa, C et al. (2010). Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther 17: 805-810.
11. Vigil, A, Martinez, O, Chua, MA and Garc?-Sastre, A (2008). Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 16: 1883-1890.
12. Drake, CG, Jaffee, E and Pardoll, DM (2006). Mechanisms of immune evasion by tumors. Adv Immunol 90: 51-81.
13. Poschke, I, Mougiakakos, D and Kiessling, R (2011). Camouflage and sabotage: Tumor escape from the immune system. Cancer Immunol Immunother 60: 1161-1171.
14. Koos, D, Josephs, SF, Alexandrescu, DT, Chan, RC, Ramos, F, Bogin, V et al. (2010). Tumor vaccines in 2010: Need for integration. Cell Immunol 263: 138-147.
15. Ferrone, S (2004). Immunotherapy dispenses with tumor antigens. Nat Biotechnol 22: 1096-1098.
16. Jevremovic, D and Vile, R (2002). The immune system in cancer: If it isn't broken, Can we fix it? In: Stuhler, G and Walden, P (eds.). Cancer Immune Therapy. Wiley VCH: Germany pp. 204-229.
17. Kottke, T, Pulido, J, Thompson, J, Sanchez-Perez, L, Chong, H, Calderwood, SK et al. (2009). Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res 69: 7767-7774.
18. Pardoll, DM (1999). Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96: 5340-5342.
19. Parmiani, G (1993). Tumor immunity as autoimmunity: Tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 14: 536-538.
20. Kottke, T, Sanchez-Perez, L, Diaz, RM, Thompson, J, Chong, H, Harrington, K et al. (2007). Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 67: 11970-11979.
21. Kottke, T, Errington, F, Pulido, J, Galivo, F, Thompson, J, Wongthida, P et al. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 17: 854-859.
22. Braxton, CL, Puckett, SH, Mizel, SB and Lyles, DS (2010). Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol 84: 3552-3561.
23. Bridle, BW, Boudreau, JE, Lichty, BD, Brunelli?e, J, Stephenson, K, Koshy, S et al. (2009). Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 17: 1814-1821.
24. Cobleigh, MA, Buonocore, L, Uprichard, SL, Rose, JK and Robek, MD (2010). A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol 84: 7513-7522.
25. Geisbert, TW, Geisbert, JB, Leung, A, Daddario-DiCaprio, KM, Hensley, LE, Grolla, A et al. (2009). Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 83: 7296-7304.
26. Schwartz, JA, Buonocore, L, Suguitan, AL Jr, Silaghi, A, Kobasa, D, Kobinger, G et al. (2010). Potent vesicular stomatitis virus-based avian influenza vaccines provide longterm sterilizing immunity against heterologous challenge. J Virol 84: 4611-4618.
27. Pulido, J, Kottke, T, Thompson, J, Galivo, F, Wongthida, P, Diaz, RM et al. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 30: 337-343.
28. Cho, HI, Reyes-Vargas, E, Delgado, JC and Celis, E (2012). A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res 72: 1986-1995.
29. Kaluza, KM, Thompson, JM, Kottke, TJ, Flynn Gilmer, HC, Knutson, DL and Vile, RG (2012). Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants. Int J Cancer 131: 844-854.
30. Rommelfanger, DM, Wongthida, P, Diaz, RM, Kaluza, KM, Thompson, JM, Kottke, TJ et al. (2012). Systemic combination virotherapy for melanoma with tumor antigenexpressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res 72: 4753-4764.
31. Kaluza, KM, Kottke, T, Diaz, RM, Rommelfanger, D, Thompson, J and Vile, R (2012). Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum Gene Ther 23: 1054-1064.
32. Boisgerault, N, Kottke, T, Pulido, J, Thompson, J, Diaz, RM, Rommelfanger-Konkol, D et al. (2013). Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther 21: 1507-1516.
33. Roda, JM, Wang, Y, Sumner, LA, Phillips, GS, Marsh, CB and Eubank, TD (2012). Stabilization of HIF-2a induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol 189: 3168-3177.
34. Shakhova, O, Zingg, D, Schaefer, SM, Hari, L, Civenni, G, Blunschi, J et al. (2012). Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14: 882-890.
35. Zhuang, D, Mannava, S, Grachtchouk, V, Tang, WH, Patil, S, Wawrzyniak, JA et al. (2008). C-MYC overexpression is required for continuous suppression of oncogeneinduced senescence in melanoma cells. Oncogene 27: 6623-6634.
36. Shibata, K, Takeda, K, Tomita, Y, Tagami, H and Shibahara, S (1992). Downstream region of the human tyrosinase-related protein gene enhances its promoter activity. Biochem Biophys Res Commun 184: 568-575.
37. Linardakis, E, Bateman, A, Phan, V, Ahmed, A, Gough, M, Olivier, K et al. (2002). Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 62: 5495-5504.
38. Gingrich, JR, Barrios, RJ, Kattan, MW, Nahm, HS, Finegold, MJ and Greenberg, NM (1997). Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57: 4687-4691.
39. Overwijk, WW, Theoret, MR, Finkelstein, SE, Surman, DR, de Jong, LA, Vyth-Dreese, FA et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569-580.
40. Fernandez, M, Porosnicu, M, Markovic, D and Barber, GN (2002). Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol 76: 895-904.